Baricitinib in Relapsing Giant Cell Arteritis
Study Details
Study Description
Brief Summary
This study will evaluate the safety and effectiveness of baricitinib in the treatment of giant cell arteritis. All participants will be taking prednisone at the start of the study. The prednisone will be reduced according to a standardized tapering schedule while participants continue to take one tablet of baricitinib daily for 52 weeks.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Detailed Description
Baricitinib, an orally administered, potent, selective and reversible inhibitor of JAK1 and JAK2 has shown preliminary safety and efficacy in chronic, immune-mediated inflammatory conditions such as rheumatoid arthritis and psoriasis. This small molecule is uniquely suited as a potential novel therapeutic agent in GCA because of its suppressive effect on both the Th17 (IL-6, IL-23) andTh1 (IL-12, IFN-γ) pathways.
This study will evaluate the safety and tolerability of baricitinib in a population of patients with relapsing GCA. The study is an open-label pilot study assessing the safety and tolerability of baricitinib (4 mg daily, oral, for 52 weeks) in addition to a standardized glucocorticoid taper. It is anticipated that adjunct baricitinib will be safe and well tolerated by patients with GCA and demonstrate preliminary efficacy as measured by reducing inflammatory markers, decreasing steroid requirements and increasing relapse-free survival.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Baricitinib Therapy 4 milligrams oral Baricitinib daily for 52 weeks |
Drug: Baricitinib
4 milligrams oral Baricitinib daily for 52 weeks
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Adverse Events [52 weeks]
The percentage of subjects who experienced greater than or equal to one adverse event
Secondary Outcome Measures
- Giant Cell Arteritis (GCA) Relapse [24 weeks, 52 weeks]
The number of subjects to experience relapse of GCA at 24 weeks and 52 weeks. As defined as: Presence of ESR ≥30 mm/hour and/or CRP ≥10 mg/L and the presence of at least one of the following: Unequivocal cranial symptoms of GCA. Unequivocal symptoms of PMR. Other features judged by the clinician to be consistent with GCA or PMR (eg, fever of unknown origin, unexplained weight loss, fatigue/ malaise, etc) for which no other aetiology was identified as causational.
- Erythrocyte Sedimentation Rate (ESR) [week 0, week 24, week 52]
ESR is a blood test that detects and monitors inflammation in the body. The normal range is 0 to 22 mm/hr for men and 0 to 29 mm/hr for women.
- C Reactive Protein (CRP) [week 0, week 24, week 52]
C-reactive protein is a substance produced by the liver in response to inflammation. Normal blood CRP levels are below 3.0 mg/L.
Eligibility Criteria
Criteria
Inclusion Criteria:
- Diagnosis of Giant Cell Arteritis (GCA) defined by the following Revised GCA Diagnosis
Criteria:
-
Age ≥50 years.
-
History of Erythrocyte Sedimentation Rate (ESR) ≥ 50 mm/hour or C-Reactive Protein (CRP) ≥ 10 mg/L.
-
Presence of at least one of the following:
-
Unequivocal cranial symptoms of GCA (new onset localized headache, scalp or temporal artery tenderness, otherwise unexplained mouth or jaw pain upon mastication).
-
Unequivocal symptoms of Polymyalgia Rheumatica (PMR), defined as shoulder and/or hip girdle pain associated with inflammatory stiffness.
-
Systemic inflammatory disease in which the presence of the fever (>38 degrees Celsius for ≥ 7 days), weight loss (> 5 pounds or 10% premorbid weight), and/or night sweats were attributable to GCA and no other cause was identified.
-
Presence of at least one of the following:
-
Temporal artery biopsy revealing features of GCA.
-
Evidence of large-vessel vasculitis by angiography or cross-sectional imaging, including but not limited to magnetic resonance angiography (MRA), computed tomography angiography (CTA), positron emission tomography-computed tomography (PET-CT) or evidence of large-vessel or temporal artery vasculitis by ultrasound (US).
- Relapse with active GCA within 6 weeks of study entry where active disease is defined by an ESR ≥30 mm/hr or CRP ≥10 mg/L AND the presence of at least one of the following:
-
Unequivocal cranial symptoms of GCA (new onset or recurrent localized headache, scalp or temporal artery tenderness, otherwise unexplained mouth or jaw pain upon mastication [i.e., jaw claudication]).
-
Unequivocal symptoms of PMR, defined as shoulder and/or hip girdle pain associated with inflammatory stiffness.
-
Other feature(s) judged by the clinician investigator to be consistent with GCA or PMR flares (e.g. fever of unknown origin, weight loss, fatigue/malaise, etc.)
- Clinically stable at baseline visit (study drug initiation) such that the subject is able to safely participate in the standardized taper regimen in the opinion of the investigator.
Exclusion Criteria
-
Presence of any other autoimmune disease (such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory arthritis, other vasculitides, scleroderma, polymyositis, dermatomyositis, or other similar systemic connective tissue diseases).
-
Subjects demonstrating symptoms of visual loss (transient or permanent blindness) or diplopia attributable to GCA.
-
Subjects with history of aortic dissection, myocardial infarction, or cerebrovascular attack attributable to GCA.
-
Has received, or is expected to receive, any live virus vaccinations (with the exception of herpes zoster vaccination) within 3 months before the first dose of study drug, during the study, or within 3 months after the last administration of the study drug. All patients who have not received the herpes zoster vaccine at screening will be encouraged (per local guidelines) to do so prior to randomization; vaccination must occur >4 weeks prior to randomization and start of investigational product. Patients will be excluded if they were exposed to herpes zoster vaccination within 4 weeks of planned randomization.
-
Organ transplant recipients.
-
Have had a major surgery within 8 weeks prior to screening or will require major surgery during the study that, in the opinion of the investigator would pose an unacceptable risk to the patient.
-
Have experienced any of the following within 12 weeks of screening: myocardial infarction (MI), unstable ischemic heart disease, stroke, or New York Heart Association Stage IV heart failure
-
Have a history or presence of cardiovascular (including but not limited to uncontrolled hypertension), respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders, or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking investigational product or interfere with the interpretation of data.
-
Are largely or wholly incapacitated permitting little or no self-care, such as being bedridden or confined to a wheelchair.
-
Have an estimated glomerular filtration rate (eGFR) of <50 mL/min/1.73 m^².
-
Have a history of chronic liver disease with the most recent available aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2 times the upper limit of normal (ULN) or the most recent available total bilirubin ≥1.5 times ULN (if available).
-
Have a history of lymphoproliferative disease; or have signs or symptoms suggestive of possible lymphoproliferative disease, including lymphadenopathy or splenomegaly; or have active primary or recurrent malignant disease; or have been in remission from clinically significant malignancy for < 5 years.
-
Subjects with uterine cervical carcinoma in situ that has been resected with no evidence of recurrence or metastatic disease for at least 3 years may participate in the study
-
Subjects with basal cell or squamous epithelial skin cancers which have been completely resected with no evidence of recurrence for at least 3 years may participate in the study.
-
Active infections, or history of recurrent infections or have required management of acute or chronic infections as evidenced by any of the following:
-
Currently on any suppressive therapy for a chronic infection (such as tuberculosis, cytomegalovirus, herpes simplex, herpes zoster, or atypical mycobacteria).
-
History or suspicion of chronic infection (e.g. prosthetic joint infection)
-
Hospitalization for treatment of infection within 60 days of baseline visit
-
Use of parenteral (IV or IM) antimicrobials (antibacterial, antifungals, antivirals, or antiparasitic agents) within 60 days of baseline or oral antimicrobials within 30 days of baseline visit for treatment of an active infection. This does not include the use of antibiotics for prophylaxis against pneumocystis pneumonia since this is considered standard of care for patients on prednisone ≥ 20 mg/day for longer than 3 consecutive months.
-
Have had symptomatic herpes zoster infection within 12 weeks prior to screening.
-
Have a history of disseminated/complicated herpes zoster [for example, multidermatomal involvement, ophthalmic zoster or Central Nervous System (CNS) involvement]
-
In the opinion of the investigator, are at an unacceptable risk for participating in the study.
-
Have known or documented diagnosis of human immunodeficiency virus (HIV).
-
Have known or documented primary immunodeficiency.
-
Have had household contact with a person with active tuberculosis (TB) and did not receive appropriate and documented prophylaxis for TB.
-
Have had evidence of active TB or have previously had evidence of active TB and did not receive appropriate and documented treatment.
-
Have evidence of latent TB as documented by a local lab positive QuantiFERON®-TB Gold test and a normal chest x-ray, unless a patient completes at least 4 weeks of appropriate treatment prior to study entry and agrees to complete the remainder of treatment while in the trial.
-
If the QuantiFERON®-TB Gold test results are positive, the patient will be considered to have latent TB and will be excluded. If the test is indeterminate, the test may be repeated once within 2 weeks of the initial value. If the repeat test results are again not negative, the subject will be considered to have latent TB (for purposes of this study) and will be excluded.
-
Exceptions include subjects with a history of active or latent TB who have documented evidence of appropriate treatment and with no history of re-exposure since their treatment was completed. (Such subjects would not be required to undergo the protocol specific TB testing, but would require a baseline chest x-ray).
-
Have a positive test for Hepatitis B Virus (HBV) defined as:
-
Positive for hepatitis B surface antigen (HBsAg), or
-
Positive for anti-hepatitis B core antibody (HBcAb) If any of the Hepatitis B tests have an indeterminate result, confirmatory testing will be performed by an alternate method.
-
Have Hepatitis C Virus (HCV) (positive for anti-hepatitis C antibody with confirmed presence of HCV).
-
Have any of the following specific abnormalities on screening tests:
-
ALT or AST > 2 x ULN
-
Total bilirubin ≥1.5 x ULN
-
Hemoglobin < 10 grams/deciliter
-
Total white blood cell count (WBC) < 2500 cells/μL)
-
Neutropenia (absolute neutrophil count [ANC] < 1200 cells/μL
-
Lymphopenia (lymphocyte count < 750 cells/μL)
-
Thrombocytopenia (platelets < 100,000 cells/μL)
-
eGFR < 50 mL/min/1.73m²
In the case of any of the aforementioned laboratory abnormalities, the tests may be repeated once within approximately 2 weeks from the initial values, and values resulting from repeat testing may be accepted for enrollment eligibility if they meet the eligibility criterion.
-
Are pregnant or breast feeding at the time of screening or enrollment.
-
Are females of childbearing potential who do not agree to use 2 forms of highly effective birth control when engaging in sexual intercourse with a male partner while enrolled in the study and for at least 4 weeks following the last dose of the study drug
-
Females of non-childbearing potential are defined as women ≥60 years of age, women
≥40 but <60 years of age what had had cessation of menses for at least 12 months, or whom who are congenitally or surgically sterile (that is have had a hysterectomy, or bilateral oophorectomy or tubal ligation)
- The following birth control methods are considered highly effective (the subject should choose 2 to be used with their male partner
- Oral, injectable, or implanted hormonal contraceptives ii. Condom with spermicidal foam, gel film, cream or suppository iii. Occlusive cap (diaphragm or cervical/vault caps) with a spermicidal foam, gel, film, cream or suppository iv. . Intrauterine device v. Intrauterine system (for example progestin-releasing coil) vi. Vasectomies male (with appropriate post-vasectomy documentation of the absence of sperm in the ejaculate)
-
Are males who do not agree to use 2 forms of highly effective birth control (see above) while engaging in sexual intercourse with females partners of childbearing potential while enrolled in the study and for 4 weeks after the last dose of the study drug.
-
Have donated more than a single unit of blood within 4 weeks prior to screening or intend to donate blood during the course of the study.
-
Have a history of chronic alcohol abuse, IV drug abuse, or other illicit drug above within the 2 years prior to screening.
-
Have previously received baricitinib for other investigational study.
-
Are unable or unwilling to make themselves available for the duration of the study and/or are unwilling to follow study restrictions/procedures
-
Are currently enrolled in, or discontinued within 4 weeks prior to screening from any other clinical trial involving an investigational product or nonapproved use of a drug or device or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
-
Are investigator site personnel directly affiliated with this study and/or their immediate families. Immediate family is defined as a spouse, parent, child, or sibling whether biological or legally adopted.
-
Have a chronic medical illness requiring the use of oral of IV glucocorticoid treatment (e.g. asthma or emphysema) during the trial or requiring long term glucocorticoid treatment such that they would not be able to safely undergone a standardized glucocorticoid taper.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Mayo Clinic | Rochester | Minnesota | United States | 55905 |
Sponsors and Collaborators
- Matthew J Koster
- Eli Lilly and Company
Investigators
- Principal Investigator: Kenneth Warrington, MD, Mayo Clinic
Study Documents (Full-Text)
More Information
Additional Information:
Publications
None provided.- 16-008993
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | Single Arm |
|---|---|
| Arm/Group Description | All participants assigned to baricitinib 4 mg daily orally for 52 weeks. |
| Period Title: Overall Study | |
| STARTED | 15 |
| COMPLETED | 14 |
| NOT COMPLETED | 1 |
Baseline Characteristics
| Arm/Group Title | Baricitinib Therapy |
|---|---|
| Arm/Group Description | 4 milligrams oral Baricitinib daily for 52 weeks Baricitinib: 4 milligrams oral Baricitinib daily for 52 weeks |
| Overall Participants | 15 |
| Age (years) [Mean (Standard Deviation) ] | |
| Mean (Standard Deviation) [years] |
72.4
(7.2)
|
| Sex: Female, Male (Count of Participants) | |
| Female |
11
73.3%
|
| Male |
4
26.7%
|
| Ethnicity (NIH/OMB) (Count of Participants) | |
| Hispanic or Latino |
0
0%
|
| Not Hispanic or Latino |
15
100%
|
| Unknown or Not Reported |
0
0%
|
| Race (NIH/OMB) (Count of Participants) | |
| American Indian or Alaska Native |
0
0%
|
| Asian |
0
0%
|
| Native Hawaiian or Other Pacific Islander |
0
0%
|
| Black or African American |
0
0%
|
| White |
15
100%
|
| More than one race |
0
0%
|
| Unknown or Not Reported |
0
0%
|
| Region of Enrollment (participants) [Number] | |
| United States |
15
100%
|
| Duration of GCA (months) [Median (Inter-Quartile Range) ] | |
| Median (Inter-Quartile Range) [months] |
9
|
| BMI (kg/m2) [Mean (Standard Deviation) ] | |
| Mean (Standard Deviation) [kg/m2] |
26.3
(3.4)
|
| Median number of prior GCA relapses (events) [Median (Full Range) ] | |
| Median (Full Range) [events] |
1
|
| Baseline Predinose dose (Count of Participants) | |
| 30 mg/day |
4
26.7%
|
| 20 mg/day |
6
40%
|
| 10 mg/day |
5
33.3%
|
Outcome Measures
| Title | Adverse Events |
|---|---|
| Description | The percentage of subjects who experienced greater than or equal to one adverse event |
| Time Frame | 52 weeks |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Baricitinib Therapy |
|---|---|
| Arm/Group Description | 4 milligrams oral Baricitinib daily for 52 weeks Baricitinib: 4 milligrams oral Baricitinib daily for 52 weeks |
| Measure Participants | 15 |
| Number [percentage of subjects] |
93
|
| Title | Giant Cell Arteritis (GCA) Relapse |
|---|---|
| Description | The number of subjects to experience relapse of GCA at 24 weeks and 52 weeks. As defined as: Presence of ESR ≥30 mm/hour and/or CRP ≥10 mg/L and the presence of at least one of the following: Unequivocal cranial symptoms of GCA. Unequivocal symptoms of PMR. Other features judged by the clinician to be consistent with GCA or PMR (eg, fever of unknown origin, unexplained weight loss, fatigue/ malaise, etc) for which no other aetiology was identified as causational. |
| Time Frame | 24 weeks, 52 weeks |
Outcome Measure Data
| Analysis Population Description |
|---|
| One subject withdrawn at week 8. Data was not collected or analyzed for week 24 and week 52 |
| Arm/Group Title | Baricitinib Therapy |
|---|---|
| Arm/Group Description | 4 milligrams oral Baricitinib daily for 52 weeks Baricitinib: 4 milligrams oral Baricitinib daily for 52 weeks |
| Measure Participants | 14 |
| 24 Weeks |
1
6.7%
|
| 52 Weeks |
1
6.7%
|
| Title | Erythrocyte Sedimentation Rate (ESR) |
|---|---|
| Description | ESR is a blood test that detects and monitors inflammation in the body. The normal range is 0 to 22 mm/hr for men and 0 to 29 mm/hr for women. |
| Time Frame | week 0, week 24, week 52 |
Outcome Measure Data
| Analysis Population Description |
|---|
| One subject withdrawn at week 8. Data was not collected or analyzed for week 24 and week 52 |
| Arm/Group Title | Baricitinib Therapy |
|---|---|
| Arm/Group Description | 4 milligrams oral Baricitinib daily for 52 weeks Baricitinib: 4 milligrams oral Baricitinib daily for 52 weeks |
| Measure Participants | 15 |
| Week 0 |
7
|
| Week 24 |
13
|
| Week 52 |
10
|
| Title | C Reactive Protein (CRP) |
|---|---|
| Description | C-reactive protein is a substance produced by the liver in response to inflammation. Normal blood CRP levels are below 3.0 mg/L. |
| Time Frame | week 0, week 24, week 52 |
Outcome Measure Data
| Analysis Population Description |
|---|
| One subject withdrawn at week 8. Data was not collected or analyzed for week 24 and week 52. NA indicates CRP levels are < 3 mg/L, but lab values do not return any actual values that are below this level of detection. Unable to use the "<" symbol. |
| Arm/Group Title | Baricitinib Therapy |
|---|---|
| Arm/Group Description | 4 milligrams oral Baricitinib daily for 52 weeks Baricitinib: 4 milligrams oral Baricitinib daily for 52 weeks |
| Measure Participants | 15 |
| Week 0 |
3.4
|
| Week 24 |
NA
|
| Week 52 |
NA
|
Adverse Events
| Time Frame | Adverse events were collected from baseline to end of study, approximately 64 weeks. | |
|---|---|---|
| Adverse Event Reporting Description | ||
| Arm/Group Title | Baricitinib Therapy | |
| Arm/Group Description | 4 milligrams oral Baricitinib daily for 52 weeks Baricitinib: 4 milligrams oral Baricitinib daily for 52 weeks | |
All Cause Mortality |
||
| Baricitinib Therapy | ||
| Affected / at Risk (%) | # Events | |
| Total | 0/15 (0%) | |
Serious Adverse Events |
||
| Baricitinib Therapy | ||
| Affected / at Risk (%) | # Events | |
| Total | 1/15 (6.7%) | |
| Blood and lymphatic system disorders | ||
| thrombocytopenia | 1/15 (6.7%) | |
Other (Not Including Serious) Adverse Events |
||
| Baricitinib Therapy | ||
| Affected / at Risk (%) | # Events | |
| Total | 14/15 (93.3%) | |
| Gastrointestinal disorders | ||
| Nausea | 6/15 (40%) | |
| Diarrhea | 1/15 (6.7%) | |
| General disorders | ||
| Edema limbs - leg | 2/15 (13.3%) | |
| Fatigue | 2/15 (13.3%) | |
| Infections and infestations | ||
| Infection not requiring antibiotics | 8/15 (53.3%) | |
| Infection requiring antibiotics | 5/15 (33.3%) | |
Limitations/Caveats
More Information
Certain Agreements
All Principal Investigators ARE employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
| Name/Title | Matthew Koster, M.D. |
|---|---|
| Organization | Mayo Clinic |
| Phone | 507-284-5800 |
| koster.matthew@mayo.edu |
- 16-008993